Levels  ||| S:0 E:7 ||| NNS
of  ||| S:7 E:10 ||| IN
Beclin  ||| S:10 E:17 ||| NNP
1  ||| S:17 E:19 ||| CD
and  ||| S:19 E:23 ||| CC
LC3  ||| S:23 E:27 ||| CD
in  ||| S:27 E:30 ||| IN
peripheral  ||| S:30 E:41 ||| JJ
blood  ||| S:41 E:47 ||| NN
mononuclear  ||| S:47 E:59 ||| NN
cells  ||| S:59 E:65 ||| NNS
of  ||| S:65 E:68 ||| IN
patients  ||| S:68 E:77 ||| NNS
with  ||| S:77 E:82 ||| IN
multiple  ||| S:82 E:91 ||| JJ
sclerosis  ||| S:91 E:101 ||| NN
and  ||| S:101 E:105 ||| CC
neuromyelitis  ||| S:105 E:119 ||| JJ
optica  ||| S:119 E:126 ||| NN
and  ||| S:126 E:130 ||| CC
its  ||| S:130 E:134 ||| PRP$
significance  ||| S:134 E:147 ||| NN
To  ||| S:147 E:150 ||| TO
explore  ||| S:150 E:158 ||| VB
the  ||| S:158 E:162 ||| DT
expression  ||| S:162 E:173 ||| NN
and  ||| S:173 E:177 ||| CC
significance  ||| S:177 E:190 ||| NN
of  ||| S:190 E:193 ||| IN
Beclin  ||| S:193 E:200 ||| NNP
1  ||| S:200 E:202 ||| CD
and  ||| S:202 E:206 ||| CC
LC3  ||| S:206 E:210 ||| CD
in  ||| S:210 E:213 ||| IN
peripheral  ||| S:213 E:224 ||| JJ
blood  ||| S:224 E:230 ||| NN
mononuclear  ||| S:230 E:242 ||| NN
cells  ||| S:242 E:248 ||| NNS
( ||| S:248 E:249 ||| -LRB-
PBMCs ||| S:249 E:254 ||| NNP
)  ||| S:254 E:256 ||| -RRB-
of  ||| S:256 E:259 ||| IN
patients  ||| S:259 E:268 ||| NNS
with  ||| S:268 E:273 ||| IN
multiple  ||| S:273 E:282 ||| JJ
sclerosis  ||| S:282 E:292 ||| NNS
( ||| S:292 E:293 ||| -LRB-
MS ||| S:293 E:295 ||| NNP
)  ||| S:295 E:297 ||| -RRB-
and  ||| S:297 E:301 ||| CC
neuromyelitis  ||| S:301 E:315 ||| JJ
optica  ||| S:315 E:322 ||| NNS
( ||| S:322 E:323 ||| -LRB-
NMO ||| S:323 E:326 ||| NNP
)  ||| S:326 E:328 ||| -RRB-
before  ||| S:328 E:335 ||| IN
and  ||| S:335 E:339 ||| CC
after  ||| S:339 E:345 ||| IN
treatment  ||| S:345 E:355 ||| NN
during  ||| S:355 E:362 ||| IN
acute  ||| S:362 E:368 ||| JJ
and  ||| S:368 E:372 ||| CC
recurrent  ||| S:372 E:382 ||| JJ
acute  ||| S:382 E:388 ||| JJ
phases ||| S:388 E:394 ||| NNS
.  ||| S:394 E:396 ||| .
All  ||| S:396 E:400 ||| DT
outpatients ||| S:400 E:411 ||| NN
,  ||| S:411 E:413 ||| ,
inpatients  ||| S:413 E:424 ||| NN
and  ||| S:424 E:428 ||| CC
healthy  ||| S:428 E:436 ||| JJ
controls  ||| S:436 E:445 ||| NNS
were  ||| S:445 E:450 ||| VBD
recruited  ||| S:450 E:460 ||| VBN
from  ||| S:460 E:465 ||| IN
our  ||| S:465 E:469 ||| PRP$
hospital  ||| S:469 E:478 ||| NN
from  ||| S:478 E:483 ||| IN
October  ||| S:483 E:491 ||| NNP
2012  ||| S:491 E:496 ||| CD
to  ||| S:496 E:499 ||| TO
April  ||| S:499 E:505 ||| NNP
2014 ||| S:505 E:509 ||| CD
.  ||| S:509 E:511 ||| .
During  ||| S:511 E:518 ||| IN
acute  ||| S:518 E:524 ||| JJ
phase ||| S:524 E:529 ||| NN
,  ||| S:529 E:531 ||| ,
PBMCs  ||| S:531 E:537 ||| JJ
from  ||| S:537 E:542 ||| IN
patients  ||| S:542 E:551 ||| NNS
with  ||| S:551 E:556 ||| IN
multiple  ||| S:556 E:565 ||| JJ
sclerosis  ||| S:565 E:575 ||| NNS
( ||| S:575 E:576 ||| -LRB-
MS ||| S:576 E:578 ||| NNP
)  ||| S:578 E:580 ||| -RRB-
and  ||| S:580 E:584 ||| CC
neuromyelitis  ||| S:584 E:598 ||| JJ
optica  ||| S:598 E:605 ||| NNS
( ||| S:605 E:606 ||| -LRB-
NMO ||| S:606 E:609 ||| NNP
) ||| S:609 E:610 ||| -RRB-
( ||| S:610 E:611 ||| -LRB-
pre  ||| S:611 E:615 ||| NN
and  ||| S:615 E:619 ||| CC
post-treatment ||| S:619 E:633 ||| NNP
)  ||| S:633 E:635 ||| -RRB-
were  ||| S:635 E:640 ||| VBD
immediately  ||| S:640 E:652 ||| RB
isolated  ||| S:652 E:661 ||| VBN
by  ||| S:661 E:664 ||| IN
Ficoll-Hypaque  ||| S:664 E:679 ||| JJ
density  ||| S:679 E:687 ||| JJ
gradient  ||| S:687 E:696 ||| JJ
centrifugation ||| S:696 E:710 ||| NN
.  ||| S:710 E:712 ||| .
And  ||| S:712 E:716 ||| CC
the  ||| S:716 E:720 ||| DT
expressions  ||| S:720 E:732 ||| NNS
of  ||| S:732 E:735 ||| IN
Beclin  ||| S:735 E:742 ||| NNP
1  ||| S:742 E:744 ||| CD
and  ||| S:744 E:748 ||| CC
LC3  ||| S:748 E:752 ||| NNP
were  ||| S:752 E:757 ||| VBD
detected  ||| S:757 E:766 ||| VBN
by  ||| S:766 E:769 ||| IN
Western  ||| S:769 E:777 ||| JJ
blot ||| S:777 E:781 ||| NN
.  ||| S:781 E:783 ||| .
And  ||| S:783 E:787 ||| CC
relapsing-remitting  ||| S:787 E:807 ||| NNP
MS  ||| S:807 E:810 ||| NNP
( ||| S:810 E:811 ||| -LRB-
RRMS ||| S:811 E:815 ||| NNP
)  ||| S:815 E:817 ||| -RRB-
and  ||| S:817 E:821 ||| CC
relapsing  ||| S:821 E:831 ||| JJ
NMO  ||| S:831 E:835 ||| NNP
( ||| S:835 E:836 ||| -LRB-
RNMO ||| S:836 E:840 ||| NNP
)  ||| S:840 E:842 ||| -RRB-
patients  ||| S:842 E:851 ||| NNS
were  ||| S:851 E:856 ||| VBD
followed  ||| S:856 E:865 ||| VBN
up  ||| S:865 E:868 ||| RP
and  ||| S:868 E:872 ||| CC
the  ||| S:872 E:876 ||| DT
expressions  ||| S:876 E:888 ||| NNS
of  ||| S:888 E:891 ||| IN
Beclin  ||| S:891 E:898 ||| NNP
1  ||| S:898 E:900 ||| CD
and  ||| S:900 E:904 ||| CC
LC3  ||| S:904 E:908 ||| CD
proteins  ||| S:908 E:917 ||| NNS
compared  ||| S:917 E:926 ||| VBN
during  ||| S:926 E:933 ||| IN
two  ||| S:933 E:937 ||| CD
acute  ||| S:937 E:943 ||| JJ
phases ||| S:943 E:949 ||| NNS
.  ||| S:949 E:951 ||| .
Compared  ||| S:951 E:960 ||| VBN
with  ||| S:960 E:965 ||| IN
normal  ||| S:965 E:972 ||| JJ
controls ||| S:972 E:980 ||| NNS
,  ||| S:980 E:982 ||| ,
the  ||| S:982 E:986 ||| DT
expression  ||| S:986 E:997 ||| NN
of  ||| S:997 E:1000 ||| IN
Beclin  ||| S:1000 E:1007 ||| NNP
1  ||| S:1007 E:1009 ||| CD
in  ||| S:1009 E:1012 ||| IN
PBMCs  ||| S:1012 E:1018 ||| JJ
from  ||| S:1018 E:1023 ||| IN
acute  ||| S:1023 E:1029 ||| JJ
phase  ||| S:1029 E:1035 ||| NN
of  ||| S:1035 E:1038 ||| IN
MS  ||| S:1038 E:1041 ||| NNP
and  ||| S:1041 E:1045 ||| CC
NMO  ||| S:1045 E:1049 ||| NNP
patients  ||| S:1049 E:1058 ||| NNS
decreased  ||| S:1058 E:1068 ||| VBD
while  ||| S:1068 E:1074 ||| IN
the  ||| S:1074 E:1078 ||| DT
expression  ||| S:1078 E:1089 ||| NN
of  ||| S:1089 E:1092 ||| IN
LC3  ||| S:1092 E:1096 ||| NNP
increased ||| S:1096 E:1105 ||| VBD
.  ||| S:1105 E:1107 ||| .
During  ||| S:1107 E:1114 ||| IN
acute  ||| S:1114 E:1120 ||| JJ
phase ||| S:1120 E:1125 ||| NN
,  ||| S:1125 E:1127 ||| ,
the  ||| S:1127 E:1131 ||| DT
expression  ||| S:1131 E:1142 ||| NN
of  ||| S:1142 E:1145 ||| IN
Beclin  ||| S:1145 E:1152 ||| NNP
1  ||| S:1152 E:1154 ||| CD
significantly  ||| S:1154 E:1168 ||| RB
increased  ||| S:1168 E:1178 ||| VBN
after  ||| S:1178 E:1184 ||| IN
treatment  ||| S:1184 E:1194 ||| NN
in  ||| S:1194 E:1197 ||| IN
MS  ||| S:1197 E:1200 ||| NNP
and  ||| S:1200 E:1204 ||| CC
NMO  ||| S:1204 E:1208 ||| NNP
patients  ||| S:1208 E:1217 ||| NNS
compared  ||| S:1217 E:1226 ||| VBN
with  ||| S:1226 E:1231 ||| IN
pre-treatment ||| S:1231 E:1244 ||| NNP
,  ||| S:1244 E:1246 ||| ,
but  ||| S:1246 E:1250 ||| CC
the  ||| S:1250 E:1254 ||| DT
expression  ||| S:1254 E:1265 ||| NN
of  ||| S:1265 E:1268 ||| IN
LC3  ||| S:1268 E:1272 ||| NNP
significantly  ||| S:1272 E:1286 ||| RB
decreased ||| S:1286 E:1295 ||| VBN
.  ||| S:1295 E:1297 ||| .
The  ||| S:1297 E:1301 ||| DT
expression  ||| S:1301 E:1312 ||| NN
of  ||| S:1312 E:1315 ||| IN
Beclin1  ||| S:1315 E:1323 ||| NNP
obviously  ||| S:1323 E:1333 ||| RB
decreased  ||| S:1333 E:1343 ||| VBN
in  ||| S:1343 E:1346 ||| IN
RRMS  ||| S:1346 E:1351 ||| NNP
and  ||| S:1351 E:1355 ||| CC
recurrent  ||| S:1355 E:1365 ||| JJ
RNMO  ||| S:1365 E:1370 ||| NNS
compared  ||| S:1370 E:1379 ||| VBN
with  ||| S:1379 E:1384 ||| IN
the  ||| S:1384 E:1388 ||| DT
previous  ||| S:1388 E:1397 ||| JJ
period ||| S:1397 E:1403 ||| NN
,  ||| S:1403 E:1405 ||| ,
but  ||| S:1405 E:1409 ||| CC
the  ||| S:1409 E:1413 ||| DT
expression  ||| S:1413 E:1424 ||| NN
of  ||| S:1424 E:1427 ||| IN
LC3  ||| S:1427 E:1431 ||| NNP
significantly  ||| S:1431 E:1445 ||| RB
increased ||| S:1445 E:1454 ||| VBN
.  ||| S:1454 E:1456 ||| .
The  ||| S:1456 E:1460 ||| DT
autophagy  ||| S:1460 E:1470 ||| JJ
level  ||| S:1470 E:1476 ||| NN
increases  ||| S:1476 E:1486 ||| NNS
in  ||| S:1486 E:1489 ||| IN
PBMC  ||| S:1489 E:1494 ||| NNP
from  ||| S:1494 E:1499 ||| IN
MS  ||| S:1499 E:1502 ||| NNP
and  ||| S:1502 E:1506 ||| CC
NMO  ||| S:1506 E:1510 ||| NNP
patients  ||| S:1510 E:1519 ||| NNS
during  ||| S:1519 E:1526 ||| IN
acute  ||| S:1526 E:1532 ||| JJ
phase ||| S:1532 E:1537 ||| NN
.  ||| S:1537 E:1539 ||| .
However  ||| S:1539 E:1547 ||| RB
it  ||| S:1547 E:1550 ||| PRP
decreases  ||| S:1550 E:1560 ||| VBZ
after  ||| S:1560 E:1566 ||| IN
treatment ||| S:1566 E:1575 ||| NN
.  ||| S:1575 E:1577 ||| .
However ||| S:1577 E:1584 ||| RB
,  ||| S:1584 E:1586 ||| ,
the  ||| S:1586 E:1590 ||| DT
autophagy  ||| S:1590 E:1600 ||| JJ
levels  ||| S:1600 E:1607 ||| NNS
significantly  ||| S:1607 E:1621 ||| RB
increase  ||| S:1621 E:1630 ||| VB
in  ||| S:1630 E:1633 ||| IN
RRMS  ||| S:1633 E:1638 ||| NNP
and  ||| S:1638 E:1642 ||| CC
RNMO ||| S:1642 E:1646 ||| NNP
.  ||| S:1646 E:1648 ||| .
And  ||| S:1648 E:1652 ||| CC
enhanced  ||| S:1652 E:1661 ||| JJ
autophagy  ||| S:1661 E:1671 ||| NN
may  ||| S:1671 E:1675 ||| MD
play  ||| S:1675 E:1680 ||| VB
its  ||| S:1680 E:1684 ||| PRP$
role  ||| S:1684 E:1689 ||| NN
in  ||| S:1689 E:1692 ||| IN
the  ||| S:1692 E:1696 ||| DT
pathogenesis  ||| S:1696 E:1709 ||| NN
of  ||| S:1709 E:1712 ||| IN
MS  ||| S:1712 E:1715 ||| NNP
and  ||| S:1715 E:1719 ||| CC
NMO ||| S:1719 E:1722 ||| NNP
.  ||| S:1722 E:1724 ||| .
